07:20 AM EST, 11/03/2025 (MT Newswires) -- TG Therapeutics ( TGTX ) reported Q3 net income Monday of $2.43 per diluted share, up from $0.02 a year earlier.

Analysts polled by FactSet expected $0.22.

Revenue for the quarter ended Sept. 30 was $161.7 million, compared with $83.9 million a year earlier.

Analysts surveyed by FactSet expected $152.1 million.

For 2025, the company raised its total global revenue guidance to about $600 million. Analysts expected $588.1 million.

Shares of the company were up 6.4% in Monday's premarket activity.